6,7-dihydroxy-2-oxo-1-benzopyran-4-carboxylic acid | 6272-31-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 6,7-dihydroxy-2-oxo-1-benzopyran-4-carboxylic acid
• 英文别名: 6,7-dihydroxy-2-oxo-2H-chromene-4-carboxylic acid；6,7-Dihydroxy-2-oxo-2H-chromen-4-carbonsaeure；6,7-Dihydroxy-2-oxo-2H-1-benzopyran-4-carboxylic acid；6,7-dihydroxy-2-oxochromene-4-carboxylic acid
• CAS: 6272-31-7
• 化学式: C₁₀H₆O₆
• 分子量: 222.154
• InChiKey: VQDPGVYDZDNPIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydroxide 作用下， 生成 6,7-dihydroxy-2-oxo-1-benzopyran-4-carboxylic acid
  参考文献：
  名称：

  v. Pechmann; v. Krafft, Chemische Berichte, 1901, vol. 34, p. 423

  摘要：

  DOI：

文献信息

• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors
  申请人：Jean Francois

  公开号：US20100168225A1

  公开（公告）日：2010-07-01

  Compounds of Formula 5 and prodrug compounds of Formula 5 wherein G 1 is H or OH; G 2 is H, R′, or CO 2 R′; G 3 , G 4 and G 5 , are each independently selected from the group consisting of: H, R′, OH, OR′, F, Cl, Br, I, NH 2 , NHR′,NR′ 2 , CN, SH, SR′, SO 3 H, SO 3 R′, SO 2 R′, OSO 3 R′, and NO 2 ; and R′ is a one to four carbon alkyl group are provided. Uses of these compounds and methods of medical treatment involving these compounds for the treatment of hepatitis C are also provided.

  提供化学式5的化合物和化学式5的前药化合物，其中G1为H或OH；G2为H、R′或CO2R′；G3、G4和G5分别独立地选自以下组中的一种：H、R′、OH、OR′、F、Cl、Br、I、NH2、NHR′、NR′2、CN、SH、SR′、SO3H、SO3R′、SO2R′、OSO3R′和NO2；R′为一至四个碳的烷基。还提供了这些化合物的用途和涉及这些化合物的医学治疗方法，用于治疗丙型肝炎。
• v. Pechmann; v. Krafft, Chemische Berichte, 1901, vol. 34, p. 423
  作者：v. Pechmann、v. Krafft

  DOI：——

  日期：——